1932

Abstract

Abstract

First identified as a powerful vasoconstrictor, endothelin has an extremely diverse set of actions that influence homeostatic mechanisms throughout the body. Two receptor subtypes, ET and ET, which usually have opposing actions, mediate the actions of endothelin. ET receptors function to promote vasoconstriction, growth, and inflammation, whereas ET receptors produce vasodilation, increases in sodium excretion, and inhibit growth and inflammation. Potent and selective receptor antagonists have been developed and have shown promising results in the treatment of cardiovascular diseases such as pulmonary arterial hypertension, acute and chronic heart failure, hypertension, renal failure, and atherosclerosis. However, results are often contradictory and complicated because of the tissue-specific vasoconstrictor actions of ET receptors and the fact that endothelin is an autocrine and paracrine factor whose activity is difficult to measure in vivo. Considerable questions remain regarding whether ET-selective or nonselective ET/ET receptor antagonists would be useful in a range of clinical settings.

Loading

Article metrics loading...

/content/journals/10.1146/annurev.pharmtox.47.120505.105134
2007-02-10
2024-04-14
Loading full text...

Full text loading...

/content/journals/10.1146/annurev.pharmtox.47.120505.105134
Loading
/content/journals/10.1146/annurev.pharmtox.47.120505.105134
Loading

Data & Media loading...

Supplemental Material

Supplementary Data

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error